← board
COLL
distress 2/10 · well-funded / low risk$34.20-1%today-31% from 52w high
Lead: pain
Revenue
$194M
Liquidity
$422M
Runway
—
Shares 1y
+3%
Price & events
-27.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
-5.7%
1W
-1.2%
1M
+5.9%
3M
-24.8%
6M
+5.5%
1Y
+1.8%
2Y
+36.0%
5Y
+72.2%
All
Overview
- Market Cap
- $1.11B
- Volume
- 13.11K
- 52 Week Range
- $29.75 – $49.84
- Total Shares
- 32.43M
- Float Shares
- 32.05M
- Short %
- 20.15%
- % Held by Insiders
- 1.16%
- % Held by Institutions
- 128.08%
- RVOL
- 0.03x
- Beta
- 0.73
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 6
- the earlier of December 2026 or upon the launch of a third-party generic equivalentGuided 40%trial initiationsecondaryNucynta · Hikma expected to launch authorized generic version of NucyntaSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- June 3, 2026conferencedata presentationsecondaryCompany will participate in Jefferies Global Healthcare ConferenceSEC 8-K
- 2026-05-12partnershipAZSTARYS · Acquisition of AZSTARYS from Corium Therapeutics for approximately $650 million in cash plus up to $135 million in milestones.SEC 8-K
- Q1 2026trial initiationsecondaryNucynta ER · Hikma expected to launch authorized generic version of Nucynta ERSEC 8-K
- 2026-03-19partnershipAZSTARYS · Collegium enters into equity purchase agreement to acquire AZSTARYS for $650M cash plus up to $135M in milestones.SEC 8-K
Approved drugs (4)
- XTAMPZA EROXYCODONE2016 · Prescription
- NUCYNTATAPENTADOL HYDROCHLORIDE2012 · Discontinued
- NUCYNTA ERTAPENTADOL HYDROCHLORIDE2011 · Prescription
- NUCYNTATAPENTADOL HYDROCHLORIDE2008 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $54 (+57% upside) · 5 analysts
- 2026-03-20HC Wainwright & Co.Buy
- 2026-03-19NeedhamBuy
- 2026-02-26NeedhamBuy
- 2026-01-09BarclaysOverweight
- 2026-01-09HC Wainwright & Co.Buy
- 2026-01-08NeedhamBuy
Competitors — pain
- LLYELI LILLY & Co$1094.4B · D3
- VRTXVERTEX PHARMACEUTICALS INC / MA$119.1B · D1
- XENEXenon Pharmaceuticals Inc.$6.3B · D3
- RAPPRapport Therapeutics, Inc.$1.9B · D3
- BHCBausch Health Companies Inc.$1.7B · D0
- CTNMContineum Therapeutics, Inc.$334M · D2
- DWTXDogwood Therapeutics, Inc.$49M · D9
- MIRAMIRA PHARMACEUTICALS, INC.$38M · D5
- CELZCREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.$3M · D7
- CASIFCASI Pharmaceuticals, Inc.$3M · D4
Recent news
- 2026-07-23Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026 - GlobeNewswire
- 2026-07-23Collegium's Aug. 6 results will be followed by an 8 a.m. webcast - Stock Titan
- 2026-07-23Is Collegium Pharmaceutical Inc (COLL) a Bargain After 3.1% Drop? GF Value Says Undervalued - GuruFocus
- 2026-07-21Faraday Future (NASDAQ:FFAI) Announces 1-for-150 Reverse Stock Split Effective at the Open of Trading on July 24, 2026 - Business Wire
- 2026-07-21KRISPY KREME® Celebrates the Sweetest Days of Summer with New Original Glazed® Blueberry Flavored Doughnut - Business Wire
- 2026-07-21Fiserv to Power Embedded Banking and Payments for Datavault AI, Including Its NIL Exchange - GlobeNewswire
- 2026-07-21Collegium Pharmaceutical Inc. (COLL) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-20Collegium Pharmaceutical to relocate headquarters to Boston By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.